4 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) JSB462, AAA617 - Prostatic Cancer, Castration-Resistant | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 138 | 2025-07-03 | 2026-10-09 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 136 | 2018-03-02 | 2026-09-28 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fibromatosis, Gingival, 2 (1) · Lethal Congenital Contracture Syndrome 2 (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Prostatic Neoplasms (3) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1)
Prednisone (2) · Abiraterone Acetate (1) · Dexamethasone (1) · Docetaxel (1) · Pluvicto (1) · cabazitaxel (1) · enzalutamide (1) · fludrocortisone acetate (1) · niraparib (1) · olaparib (1)
Cancer Research UK (1) · Janssen Research & Development, LLC (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1)
Canada (3) · Israel (3) · Italy (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · France (2) · Germany (2) · South Korea (2) · Taiwan (2) · Austria (1) · Belgium (1) · Chile (1) · China (1)
2017 (1), 2023 (1)